3XV Stock Overview
A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Xvivo Perfusion AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 42.65 |
| 52 Week High | SEK 46.80 |
| 52 Week Low | SEK 30.25 |
| Beta | 2.14 |
| 1 Month Change | 9.36% |
| 3 Month Change | -0.70% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 39.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3XV | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.7% | 0.9% | 1.3% |
| 1Y | n/a | -9.7% | 9.0% |
Return vs Industry: Insufficient data to determine how 3XV performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 3XV performed against the German Market.
Price Volatility
| 3XV volatility | |
|---|---|
| 3XV Average Weekly Movement | 4.8% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3XV has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 3XV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 161 | Christoffer Rosenblad | www.xvivogroup.com |
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.
Xvivo Perfusion AB (publ) Fundamentals Summary
| 3XV fundamental statistics | |
|---|---|
| Market cap | €1.34b |
| Earnings (TTM) | €17.78m |
| Revenue (TTM) | €65.34m |
75.6x
P/E Ratio20.6x
P/S RatioIs 3XV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3XV income statement (TTM) | |
|---|---|
| Revenue | SEK 750.59m |
| Cost of Revenue | SEK 192.08m |
| Gross Profit | SEK 558.52m |
| Other Expenses | SEK 354.25m |
| Earnings | SEK 204.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 28, 2025
| Earnings per share (EPS) | 6.48 |
| Gross Margin | 74.41% |
| Net Profit Margin | 27.21% |
| Debt/Equity Ratio | 0% |
How did 3XV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 10:23 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xvivo Perfusion AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dylan van Haaften | Bryan Garnier & Co |
| Maria Vara Fernández | Bryan Garnier & Co |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |